Immuno-Stimulating Peptide Derived From Hmgb1 Is More Effective Than the N-Terminal Domain of Gp96 As an Endogenous Adjuvant for Improvement of Protein Vaccines

Immuno-Stimulating Peptide Derived From Hmgb1 Is More Effective Than the N-Terminal Domain of Gp96 As an Endogenous Adjuvant for Improvement of Protein Vaccines Publisher Pubmed

Talebi S¹ ; Bolhassani A² ; Azad TM³ ; Arashkia A⁴ ; Modaresi MH⁵

Show Affiliations

1. Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
2. Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
3. Virology Centre, School of Public Health, Tehran University of Medical Sciences (TUMS), Tehran, Iran
4. Department of Virology, Pasteur Institute of Iran, Tehran, Iran
5. Department of Medical Genetics, Faculty of Medicine, Tehran University of Medicine Science, Tehran, Iran

Source: Protein and Peptide Letters Published:2017

Abstract

Up to now, different protein vaccine modalities against human papillomavirus (HPV) have been designed to control cervical cancer. The important issue is to increase their immunogenicity using appropriate adjuvants. Among heat shock proteins (HSPs), glycoprotein 96 (Gp96) and its Nterminal region (NT-gp96) have attracted a specific interest in stimulation of antigen-specific immune responses in vivo. Furthermore, the potency of high mobility group box 1 (HMGB1) protein and its fragment (Hp91) was reported to enhance the desired immune responses against various disorders. In this study, the recombinant (r) HPV16 E7 and rNT-gp96 proteins were generated in bacterial expression system. Mice were vaccinated three times with E7 antigen mixed with Montanide, Hp91, and NT-gp96 as the adjuvant and their preventive and therapeutic efficiencies were evaluated in a murine tumor model. Mice vaccinated with E7 co-delivered by Hp91 peptide induced higher IgG2a and IFN-responses in comparison with E7 co-injected with Montanide and NT-gp96 protein suggesting a strong Th1 cellular immune response. The data showed that vaccination with noncovalent rE7 + rNT-gp96 complex delayed the tumor growth as compared to control groups. Mice immunized with rE7 + Montanide and rE7 + Hp91 protected 100% of mice versus 75% survival in groups vaccinated with rE7 + rNT-gp96 after TC-1 tumor challenge. The percentage of tumor free mice was decreased in group immunized with rE7 + rNT-gp96 in therapeutic experiments (50%). These results demonstrated that Hp91 peptide is a safe and strong adjuvant against rNT-gp96 with the potent anti-tumor effects similar to Montanide adjuvant. © 2017 Bentham Science Publishers.

2. In Silico Approach for Designing a Novel Recombinant Fusion Protein As a Candidate Vaccine Against Hpv, Current Proteomics (2021)

3. Generation of the Fluorescent Hpv16 E7 Protein for Detection of Delivery in Vitro, Protein and Peptide Letters (2018)

4. Hcv Core/Ns3 Protein Immunization With “N-Terminal Heat Shock Gp96 Protein (Rnt (Gp96))” Induced Strong and Sustained Th1-Type Cytokines in Immunized Mice, Vaccines (2021)

5. Hpv16-E7 Protein T Cell Epitope Prediction and Global Therapeutic Peptide Vaccine Design Based on Human Leukocyte Antigen Frequency: An In-Silico Study, International Journal of Peptide Research and Therapeutics (2021)

6. Human Neutrophil Peptide 1 As Immunotherapeutic Agent Against Leishmania Infected Balb/C Mice, PLoS Neglected Tropical Diseases (2017)

7. In Vitro Expression of Hpv16 E7 Linked to Hmgb1 Immunoadjuvant in Mammalian Cells, Bratislava Medical Journal (2016)

Experts (# of related papers)

View all Related Experts

Katayoun Samimi Rad (2)

Mohammad Vasei (1)

Style	Citing Format
MLA	Talebi S, et al.. "Immuno-Stimulating Peptide Derived From Hmgb1 Is More Effective Than the N-Terminal Domain of Gp96 As an Endogenous Adjuvant for Improvement of Protein Vaccines." Protein and Peptide Letters, vol. 24, no. 3, 2017, pp. 190-196.
APA	Talebi S, Bolhassani A, Azad TM, Arashkia A, Modaresi MH (2017). Immuno-Stimulating Peptide Derived From Hmgb1 Is More Effective Than the N-Terminal Domain of Gp96 As an Endogenous Adjuvant for Improvement of Protein Vaccines. Protein and Peptide Letters, 24(3), 190-196.
Chicago	Talebi S, Bolhassani A, Azad TM, Arashkia A, Modaresi MH. "Immuno-Stimulating Peptide Derived From Hmgb1 Is More Effective Than the N-Terminal Domain of Gp96 As an Endogenous Adjuvant for Improvement of Protein Vaccines." Protein and Peptide Letters 24, no. 3 (2017): 190-196.
Harvard	Talebi S et al. (2017) 'Immuno-Stimulating Peptide Derived From Hmgb1 Is More Effective Than the N-Terminal Domain of Gp96 As an Endogenous Adjuvant for Improvement of Protein Vaccines', Protein and Peptide Letters, 24(3), pp. 190-196.
Vancouver	Talebi S, Bolhassani A, Azad TM, Arashkia A, Modaresi MH. Immuno-Stimulating Peptide Derived From Hmgb1 Is More Effective Than the N-Terminal Domain of Gp96 As an Endogenous Adjuvant for Improvement of Protein Vaccines. Protein and Peptide Letters. 2017;24(3):190-196.
BibTex	@article{ author = {Talebi S and Bolhassani A and Azad TM and Arashkia A and Modaresi MH}, title = {Immuno-Stimulating Peptide Derived From Hmgb1 Is More Effective Than the N-Terminal Domain of Gp96 As an Endogenous Adjuvant for Improvement of Protein Vaccines}, journal = {Protein and Peptide Letters}, volume = {24}, number = {3}, pages = {190-196}, year = {2017} }
RIS	TY - JOUR AU - Talebi S AU - Bolhassani A AU - Azad TM AU - Arashkia A AU - Modaresi MH TI - Immuno-Stimulating Peptide Derived From Hmgb1 Is More Effective Than the N-Terminal Domain of Gp96 As an Endogenous Adjuvant for Improvement of Protein Vaccines JO - Protein and Peptide Letters VL - 24 IS - 3 SP - 190 EP - 196 PY - 2017 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract